Cerba Research Montpellier meets the needs of its customers by developing immunohistochemistry (IHC) protocols allowing the detection of targets of interest in tissue sections. In the context of clinical trials, these protocols must meet the requirements of the authorities in order to assure the client of the conformity of the results obtained on the precious patient samples.
Faced with the diversity of parameters evaluated, and types of possible evaluation, in the implementation of these custom protocols, the automation of data analysis quickly became a need.
Thanks to various JMP tools, we were able to set up analysis automation allowing us to save time and standardize our protocol performance reports (thanks to the "Dashboard") by including statistical and graphical data. This process, registered as an Add-in, is available to all our users, thus facilitating our procedures.
Biography
Marie Gérus-Durand has been working at Cerba Research as a Validation Engineer since March 2020. She is in charge of validating immunohistochemistry protocols for their use in clinical trials and analyzing the associated data to define whether or not the protocols meet regulatory requirements.
Company presentation
Cerba Research is the research division of Cerba HealthCare, a major player in medical diagnostics.
We are an international centralized laboratory. Our network of specialized laboratories guarantees you global coverage on each continent from the research phases to the advanced clinical development phases. Our expertise extends from diagnostic tests, development, validation of biomarkers, to the management of patient data.
We work closely with government agencies, NGOs, as well as medium and large pharmaceutical companies to advance medical research.
